盐酸纳美芬 | 1228646-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 中文名称: 盐酸纳美芬
• 英文名称: Nalmefene hydrochloride monohydrate
• 英文别名: (4R,4aS,7aS,12bS)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydrate;hydrochloride
• CAS: 1228646-72-7
• 化学式: C21H28ClNO4
• 分子量: 393.9
• InChiKey: DHNDBWKCHBYAIX-BGXRRRKMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.11
• 重原子数：
  27
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  53.9
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• [EN] NALMEFENE SALTS AS MEDICAMENTS FOR REDUCING ALCOHOL CONSUMPTION OR FOR PREVENTING EXCESSIVE ALCOHOL CONSUMPTION<br/>[FR] SELS DE NALMÉFÈNE EN TANT QUE MÉDICAMENTS POUR RÉDUIRE LA CONSOMMATION D'ALCOOL OU EMPÊCHER LA CONSOMMATION EXCESSIVE D'ALCOOL
  申请人：LUNDBECK & CO AS H

  公开号：WO2015004240A1

  公开（公告）日：2015-01-15

  The present invention relates to new nalmefene salts which salts fall within at least one of the two following categories: non-hydrate forming salts and non-solvate forming salts. In particular, the invention relates to the hydrogen adipate salt, the hydrogen malonate salt, the lactate salt, the hydrogen fumarate salt, the hydrogen succinate salt, the benzene sulfonate salt, the hydrogen maleate salt and the salicylate salt of nalmefene. The present invention also relates to such salts for use in therapy.

  本发明涉及新的纳尔美芬盐，这些盐属于以下两类至少一类：不产生水合物的盐和不产生溶剂物的盐。特别地，本发明涉及纳尔美芬的氢顺己二酸盐、氢丙二酸盐、乳酸盐、氢富马酸盐、氢琥珀酸盐、苯磺酸盐、氢马来酸盐和水杨酸盐。本发明还涉及这些盐在治疗中的应用。
• [EN] NALMEFENE HYDROCHLORIDE DIHYDRATE<br/>[FR] CHLORHYDRATE DE NALMEFENE DIHYDRATÉ
  申请人：LUNDBECK & CO AS H

  公开号：WO2010063292A1

  公开（公告）日：2010-06-10

  The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dehydrate.

  本发明涉及Nalmefene盐酸二水合物、制造Nalmefene盐酸二水合物的方法、包含Nalmefene盐酸二水合物的药物组合物以及包括给予Nalmefene盐酸二水合物的治疗方法。
• NALMEFENE HYDROCHLORIDE DIHYDRATE
  申请人：Lopez de Diego Heidi

  公开号：US20110251228A1

  公开（公告）日：2011-10-13

  The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dehydrate.

  本发明涉及纳尔美芬盐酸盐二水合物、制备纳尔美芬盐酸盐二水合物的方法、包含纳尔美芬盐酸盐二水合物的药物组合物以及通过给予纳尔美芬盐酸盐二水合物的方法进行治疗的方法。
• Nalmefene hydrochloride dihydrate
  申请人：H. Lundbeck A/S

  公开号：EP2441766A1

  公开（公告）日：2012-04-18

  The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dihydrate.

  本发明涉及盐酸纳美芬二水合物、盐酸纳美芬二水合物的制造方法、包含盐酸纳美芬二水合物的药物组合物以及包括施用盐酸纳美芬二水合物的治疗方法。
• Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
  申请人：Southwest Research Institute

  公开号：US10927121B1

  公开（公告）日：2021-02-23

  Methods for removing residual solvent from Nalmefene Hydrochloride (HCl) and producing crystalline Nalmefene HCl monohydrate, monosolvate or crystalline Nalmefene HCl dihydrate are described. In embodiments, the methods include recrystallizing Nalmefene HCl from a solvate that includes Nalmefene HCl, water, and a first solvent, wherein the first solvent has a molar volume of at least 98 cm3. Crystalline Nalmefene HCl with a desirably low amount of residual solvent is also described.

  本发明描述了从盐酸纳美芬（HCl）中去除残留溶剂并生产结晶盐酸纳美芬一水合物、单溶物或结晶盐酸纳美芬二水合物的方法。在实施例中，这些方法包括从包括盐酸纳美芬、水和第一溶剂的溶液中重结晶盐酸纳美芬，其中第一溶剂的摩尔体积至少为 98 立方厘米。此外，还介绍了具有理想低残留溶剂量的结晶盐酸纳美芬。